Beryllium Research Symposium: Basic Mechanisms and Human Health
June 25- 26, 2002
National Library of Medicine, Bethesda, MD

 Contents

 Introduction

 Welcome

 Agenda

 Session 1

 Session 2

 Session 3

 Session 4

 Session 5

 Attendees

• Electrostatic Potential onHLA-DPB1*1701 and HLA-DPB1*0401:Implications for Putative Mechanism of Chronic Beryllium Disease
  Eugene Demchuk; National Institute for Occupational Safety and Health, Morgantown, WV (also available as a PowerPoint file)
  

• Chemicals and Immunologic Lung Disease:Gene and Environment
  Meinir G Jones; NHLI @ ICSM; London (also available as a PowerPoint file)

• Physicochemical Determinants of Beryllium Toxicity using in vitro and in vivo Models
  Gregory L. Finch; Drug Safety Evaluation; Pfizer Global Research & Development; Groton, CT (also available as a PowerPoint file)

• Dosimetry of Beryllium in an Animal Model by Accelerator Mass Spectrometry (AMS)
  Marina Chiarappa-Zucca; Lawrence Livermore National Laboratory University of California (also available as a PowerPoint file)

• Beryllium Stimulates a Local Angiotensin System in Chronic Beryllium Disease
  LA Maier; National Jewish Medical and Research Center (also available as a PowerPoint file)

• Beryllium-Induced Macrophage Apoptosis in Chronic Beryllium Disease
  R.T. Sawyer, National Jewish Medical and Research Center, University of Colorado Health Sciences Center (also available as a PowerPoint file)
  

• Characterization of Beryllium-Specific Memory CD4+ T Cells in Patients with Chronic Beryllium Disease
  Andrew P. Fontenot, Scott J. Canavera, Laia Gharavi, Lee S. Newman, and Brian L. Kotzin

• HLA-DP-Unrestricted TNF-a Release in Be-Stimulated
  PBMC from Berylliosis Patients
  Massimo Amicosante, Floriana Berretta, Alberto Franchi, Paola Rogliani, Chiara Dotti, Monica Losi, Raed Dweik, and Cesare Saltini

• Design, Engineering and Production of Human Recombinant
  T Cell Receptor Ligands Derived from HLA-DP
  Gregory G. Burrows, Roberto Meza-Romero, Jeff Mooney, Justin W. Chang, Hans Peter Bachinger, and
  Jianya Huan

• A Flow Cytometric Assay for Beryllium Sensitization: Screening and Mechanistic Applications
  A.J. Jabbour, R.A. Ponce, M.T. Rosato, T.J. Kavanagh, L.S. Newman, T.K. Takaro, and E.M. Faustman

• Beryllium Stimulates a Local Angiotensin System in Chronic Beryllium Disease
  T. Hendry-Hofer, A.F. Fontenot, E.A. Barker, M. Boguniewicz, L.S. Newman, and L.A. Maier

• High Levels of Nitric Oxide (NO) in Exhaled Breath in Patients with Chronic Beryllium Disease
  R.A. Dweik, D. Laskowski, and S.C. Erzurum

• Nitric Oxide (NO) Attenuation of Interferon Gamma (IFN-Gamma) Responses in Chronic Beryllium Disease (CBD): Evidence For Mechanisms Independent of Interleukin (IL)-18
  M.J. Thomassen, C. Farver, R.A. Dweik, D. Culver, B. Yen-Lieberman, M. Kavuru, and B.P. Barna

• Dosimetry of Beryllium in an Animal Model by Accelerator Mass Spectrometry
  M.L. Chiarappa-Zucca, R.C. Finkel, J.E. McAninch, R.E. Martinelli and K.W. Turteltaub

• Identification of Non-Toxic Beryllium-Chelating Porphyrins and Method of Delivery to Mice in an Attempt to Reduce the Lung Beryllium (Be) Burden in Chronic Beryllium Disease (CBD)
  Jim Klostergaard and George P. Sakalosky

• Surface Area of Respirable Beryllium Metal, Oxide, and Copper Alloy Aerosols and Implications for Assessment of Exposure Risk of Chronic Beryllium Disease
  A.B. Stefaniak, M.D. Hoover, R.M. Dickerson, E.J. Peterson, G.A. Day, P.N. Breysse, M.S. Kent, and R.C. Scripsick

• Examining Beryllium Chemistry with Modern Analytical Techniques
  M. Sutton, S.R. Burastero, C. Mundy, and J. Quong

• Functional TNF-a Promoter Polymorphisms Associated
  With Chronic Beryllium Disease and Beryllium-Induced
  TNF-a
  L.A. Maier, R.T. Sawyer, T. Hendry-Hofer, C. Parsons, R. Bauer, D. McGrath, P. Lympany, R. duBois and L.S. Newman

• Association of HLA Class II Markers and Beryllium Hypersensitivity and Disease: Reevaluation of Previously Published Data after 4-8 Years of Follow-up
  C. Saltini and M. Rossman

• Electrostatic Potential on HLA-DP*1701 and HLA-DP*0401: Implications for Putative Mechanism of Chronic Beryllium Disease
  James A. Snyder, Ainsley Weston, Sally T. Tinkle, and Eugene Demchuk

• Cutaneous Application of Beryllium Salts and Oxide Particles Produces Beryllium-Specific Peripheral Sensitization in the C3H/HeOuJ Mice
  Sally Tinkle, James Antonini, Jenny Roberts, Rebecca Salmen, Karyn Depree, and Melanie Flint

• In Vitro Transformation of Phagocytized Beryllium Oxide Particles in the Murine J774A.1 Cell
  G.A. Day, A.B. Stefaniak, M.D. Hoover, R.M. Dickerson, E.J. Peterson, N.A. Esmen, and R.C. Scripsick

• The Mouse Deep Lung is Exposed to Respirable Particles Administered by Pharyngeal Aspiration
  A.F. Hubbs, G.V.S. Rao, M. Kashon, R. Salmen, L.A. Battelli, P. Willard, J. Antonini, D.N. Weissman, and S. Tinkle

• Beryllium-Induced Macrophage Apoptosis in Chronic
  Beryllium Disease
  R.T. Sawyer, V.A. Fadok, L.A. Maier, L.A. Kittle, J.M. Routes, and L.S. Newman